Skip to content

Real-World Study of Cutaneous Malignant Tumors in Chinese Population: A Pathological Diagnosis-Based Analysis of Clinical Characteristics and Prognosis

Real-World Study of Cutaneous Malignant Tumors in Chinese Population: A Pathological Diagnosis-Based Analysis of Clinical Characteristics and Prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120668
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-04-20
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous malignant tumor

Interventions

Observation Group of Skin Malignant Tumors:None

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with primary skin-derived malignant tumors through skin tissue pathological biopsy include epidermal malignant tumors, malignant tumors of skin appendages, malignant melanoma, malignant vascular tumors, neurogenic and neuroendocrine malignant tumors, smooth muscle and adipose tissue malignant tumors, fibrous connective tissue malignant tumors, and cutaneous lymphomas, etc. 2. Sign the informed consent form (the retrospective registration registration part can be exempted from informed consent).

Exclusion criteria

Exclusion criteria: 1. Without a pathological diagnosis of skin tissue 2. Suffering from a special genetic syndrome that increases the risk of developing skin malignancies, such as dyschromic ichthyosis, basal cell nevus syndrome, ocular-skin albinism, dystrophic epidermolysis bullosa, Bazex-Dupre-Christol syndrome, etc. 3. Skin tumors that are not originated from the skin 4. Unable to cooperate due to cognitive dysfunction and without the assistance of family members

Design outcomes

Primary

MeasureTime frame
European organisation for research and treatment of cancer core quality of life;Dermatology life quality index;

Secondary

MeasureTime frame
Size of cutaneous tumors;Complete response;Recurrence-free survival;

Countries

China

Contacts

Public ContactChang Jianmin

Beijing Hospital

changjm0417@126.com+86 10 8513 7232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026